Neuphoria Provides a Review of 2024 and Highlights 2025 Plans


BURLINGTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today provided a review of 2024 and highlighted plans for 2025.

Original post:
Neuphoria Provides a Review of 2024 and Highlights 2025 Plans

Related Posts